- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Lilly reorganization to cut 5,500 positions over 2 years
September 14, 2009
J.K. WallEli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
MoreLocal health care industry tries to capitalize on migraine headaches
September 12, 2009
J.K. WallMigraines cost American employers $20 billion a year in decreased worker productivity. Such
a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based
pharmaceutical giant Eli Lilly and Co.
MoreLilly paid doctors to prescribe Zyprexa, notes say
September 8, 2009
IBJ StaffEli Lilly and Co. paid doctors in South Carolina for participating in a speakers' program in exchange for prescribing the
antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.
MoreAIT Laboratories leaps up Inc.'s list
August 24, 2009
IBJ StaffThe Indianapolis-based forensics, clinical and pharmaceutical testing firm now ranks 598, up from 1,466 a year ago. The list
is based on percentage of revenue growth.
MoreLilly drops osteoporosis pipeline drug
August 18, 2009
J.K. WallEli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating
the company’s attempts to find revenue before losing patent protection on its bestseller.
MoreLilly pays $224,000 to area doctors
August 17, 2009
IBJ StaffIt’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But
Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first
quarter.
MoreLilly's Effient launch just one of its many challenges
August 3, 2009
Greg AndrewsEli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
MoreArcadia hopes health care reform means more revenue
August 3, 2009
J.K. WallThe CEO of Indianapolis-based Arcadia Resources said the environment is perfect for his company's fast-growing DailyMed
service.
MoreLilly cancels trials for experimental MS drug
July 28, 2009
J.K. WallEli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
MorePotential obesity breakthrough boosts Marcadia
July 20, 2009
J.K. WallFavorable article in prestigious journal could draw attention to Carmel biotech startup.
MoreDrug industry funds Democrat-led panel on health care reform
July 20, 2009
J.K. WallThe pharmaceutical industry—which for two decades has given twice as much in campaign donations
to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis
to argue its position on health care reform.
MoreProfessors go online to revolutionize drug discovery
July 20, 2009
IBJ StaffTwo chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and
all over the world.
MoreBREAKING: FDA approves Lilly blood-thinner prasugrel
July 10, 2009
J.K. WallEli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner,
according to Bloomberg News.
MoreLilly cancer drug OK'd for new use
July 6, 2009
J.K. WallEli Lilly and Co.'s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales
of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
MoreProfs trying to revolutionize drug discovery process
June 22, 2009
IBJ StaffTwo chemistry professors at IUPUI are laboring to create the McDonald's of research laboratories—a model that's low-cost
and can spread around the world.
MoreWith Byetta's sales stalled, Lilly unveils its own competitor
June 15, 2009
IBJ StaffWhile Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it's developing a potential
competitor to Byetta all on its own.
MoreBiotechnology firm boosts its protein biz
June 8, 2009
IBJ StaffGreenwood-based Elona Biotechnologies said it has created two subsidiaries to boost its biosimilar/biogeneric/follow-on protein
business.
MoreWith pharma famine looming, Lilly relying on snack-size deals
May 4, 2009
J.K. WallCompared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using
a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
MoreIndiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individuals
April 13, 2009
Chris O'MalleyIndiana is becoming not only a hotbed of "pharmacogenomics" research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
MoreIn spite of criticism, Lilly saves lives
March 30, 2009
Steven J.My wife, Becky, is alive today because of Lilly and its trial drug Enzastaurin, a great surgeon, and a terrific team of local
doctors.
MoreLogistics firm grows
February 16, 2009
MD Logistics has completed a coldstorage facility for pharmaceutical products in its hometown of Plainfield.
MoreBiotech push may help offset generic competition; some analysts skeptical
February 2, 2009
J.K. WallLilly executives want to make biotech their top focus.
MoreCarmel startup lands $12M in venture capital
January 19, 2009
Peter SchnitzlerCarmel startup Waterstone Pharmaceuticals Inc., which hopes to research drug components here and make them in China, has just
raised $12 million in venture
capital—despite the recession and a deep freeze in financial markets.
MoreOBS Medical hopes to capture pharma's heart
January 19, 2009
J.K. WallThe latest product to come out of Carmel-based OBS Medical may be just what the doctors ordered. The doctors working for major
pharmaceutical companies, that is.
MoreTarganta receives rescue line for drug
January 19, 2009
A former Eli Lilly and Co. antibiotic being developed in Indianapolis will live to try again. The company developing the drug,
Massachusetts-based Targanta Therapeutics Inc., has agreed to be acquired by New Jersey-based
The Medicines Co. for $42 million.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Doug Henning!
These guy were thugs — they grew up in freaking Haughville! Smh, sigh. If the mayor needs/wants "quality" Black Hoosiers who are NOT corrupt, give me a call — I know plenty. Land bank info here - http://www.kubepharm.com/indylandbank/IndyLandBank.html
Magician and illusionist!
The basic idea of nice apartments with parking and retail is a good one, but this design seems overwhelmingly big/tall for Broad Ripple. The size could be disguised a bit with lots of big trees/landscaping, but the complex is too massive to blend in easily. That section of canal between College and Westfield will also need to be upgraded on both sides. Nice apartments facing onto a nice promenade with shade trees/plantings could bring together the canal towpath/Monon recreation, the outdoor seating at existing restaurants, and this project into something that upgrades the whole area. A plan for the whole stretch makes more sense than facing nice new housing onto what looks like a ditch. Is there a plan? Does the public have input? Who pays? The apartment idea seems to be reasonable, but Whole Foods is not a good idea for appropriate retail. Besides the store being physically too big, there are already Fresh Market at 54xCollege and Whole Foods in Nora for fancy groceries. Good Earth and Kroger are within walking distance of the Shell site. There are at least 7 grocery stores within a safe bike ride. Whole Foods would add nothing but traffic congestion. This design is on the right track, but there needs to be more work done to ensure that it blends in with and enhances the existing community. A project that large will set a tone for that whole part of town. It could be a real asset, but only if done right.
I did not move to Zionsville to live in Carmel. This and the subsequent developments to follow will ensure a vanilla uniformity of strip malls and apartment buildings as we seek to bring our town down to the least common denominator. We were warned before recent elections that pro-development council members would make sure their friends (landowners and developers) would be able to make their millions off of the exploitation of Zionsville. Why in God's name would we sell out the best preserved small town in the State of Indiana?